Daclatasvir

DEA Class; Rx

Common Brand Names; Daklinza

• NS5A Protein Inhibitor Antivirals for Hepatitis C

Hepatitis C virus (HCV) NS5A inhibitor
For use with sofosbuvir and with or without ribavirin to treat genotypes 1 and 3 chronic HCV infections
Consider testing for NS5A resistance-associated polymorphisms prior to treating cirrhotic patients with HCV genotype 1a infections

In certain patient populations, daclatasvir is recommended for use with ribavirin; therefore, any contraindication to ribavirin will also apply to the combination regimen. See the ribavirin monograph for additional information.

Daclatasvir is approved for use in patients coinfected with hepatitis C and HIV. HIV treatment guidelines recommend all patients presenting with HIV infection undergo testing for hepatitis C, with continued annual screening advised for those persons considered high risk for acquiring hepatitis C.

• hepatic failure
• hepatitis B exacerbation
• anemia 
• hyperbilirubinemia
• headache
• fatigue 
• nausea 
• rash 

—

No human data are available regarding use of daclatasvir during pregnancy, and it is unknown if the drug poses a risk to the fetus or is associated with adverse reactions on the human reproductive system.

According to the manufacturer, it is not known if daclatasvir is excreted in human milk. Consider the benefits of breast-feeding, the risk of infant drug exposure, and the risk of an untreated or inadequately treated condition.